MHB018A
Stories
-
Minghui and ASKA enter exclusive license for MHB018A in Japan
Minghui Pharmaceutical and ASKA Pharmaceutical announced an exclusive license agreement for the development and commercialization of MHB018A in Japan, with ASKA receiving rights to seek regulatory approval and commercialize the antibody. The agreement includes an upfront payment of USD 110 million and potential milestone payments of up to USD 330 million, plus tiered royalties up to mid-30 % on net sales in Japan.